Form 4: Teladoc Health Executive Stephany Verstraete Reports Stock Transactions
SEC Form 4 Filing
Chief Marketing Officer of Teladoc Health, Stephany Verstraete, reports acquisition and disposal of company stock and derivative securities.
Summary
- Stephany Verstraete, Chief Marketing Officer of Teladoc Health, filed a Form 4 detailing changes in beneficial ownership.
- On May 31, 2024, Verstraete acquired 1,109 shares of common stock through the conversion of performance stock units and 4,659 shares through the conversion of restricted stock units.
- On June 3, 2024, she disposed of 2,096 shares of common stock at a price of $11.157 per share to cover tax withholding obligations.
- Following these transactions, Verstraete beneficially owns 60,158 shares of Teladoc Health common stock.
- She also holds 7,767 performance stock units, 4,212 restricted stock units from a 2022 grant, and 22,787 restricted stock units from a 2023 grant.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The filing reflects routine transactions related to executive compensation. There's no indication of significant positive or negative sentiment.
Positives
- The acquisition of shares through the vesting of stock units indicates a continued alignment of the executive's interests with the company's performance.
Negatives
- The sale of shares to cover tax obligations, while common, slightly reduces the executive's direct stake in the company.
Risks
- Executive stock transactions can sometimes be interpreted as a signal of the company's prospects, although in this case, the sale appears to be routine for tax purposes.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies and are regularly monitored by investors for insights into management's perspective on the company's value and future prospects. This filing is a routine disclosure.
Comparison to Industry Standards
- Executive compensation packages, including stock and option awards, are standard practice among publicly traded companies like Teladoc Health.
- Companies such as Amwell and Accolade, which operate in similar telehealth markets, also utilize stock-based compensation to incentivize their executives.
- The vesting schedules and terms of these equity grants are generally aligned with industry norms to retain and motivate key personnel.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.
- Shareholders may view the transactions as a routine part of executive compensation.
Key Dates
| Date | Description |
|---|---|
| March 1, 2022 | Reporting person was granted 16,844 restricted stock units, vesting one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter. |
| March 3, 2023 | Reporting person was granted 39,063 restricted stock units, vesting one-third on March 1, 2024, with the remainder vesting in eight substantially equal quarterly installments thereafter. |
| March 1, 2024 | The reporting person earned 13,313 performance stock units, vesting one-third on March 1, 2024, with the remainder vesting in eight substantially equal quarterly installments thereafter. |
| May 31, 2024 | Date of stock acquisition through conversion of performance and restricted stock units. |
| June 3, 2024 | Date of stock disposal to cover tax withholding obligations. |
| June 4, 2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.